Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma

Chirag Nepal, Colm J. O'Rourke, Douglas V.N.P. Oliveira, Andrzej Taranta, Steven Shema, Prson Gautam, Julien Calderaro, Andrew Barbour, Chiara Raggi, Krister Wennerberg, Xin W. Wang, Anja Lautem, Lewis R. Roberts, Jesper B. Andersen – 26 December 2017 – Intrahepatic cholangiocarcinoma remains a highly heterogeneous malignancy that has eluded effective patient stratification to date. The extent to which such heterogeneity can be influenced by individual driver mutations remains to be evaluated.

Outcomes after multiple courses of granulocyte colony‐stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial

Nipun Verma, Amritjyot Kaur, Ratiram Sharma, Ashish Bhalla, Navneet Sharma, Arka De, Virendra Singh – 26 December 2017 – Decompensated cirrhosis (DC) carries a high mortality. Liver transplantation (LT) is the treatment of choice; however, the limited availability of donor organs has resulted in high waitlist mortality. The present study investigated the impact of multiple courses of granulocyte‐colony stimulating factor (G‐CSF) with or without growth hormone (GH) in these patients.

Hypothermic machine perfusion in liver transplantation

R. Cutler Quillin, James V. Guarrera – 26 December 2017 – A finite supply of donor organs has led many transplant centers to accept marginal liver allografts with increasing frequency. These allografts may be at higher risk of primary nonfunction, early allograft dysfunction, and other recipient complications following liver transplantation. Machine perfusion preservation is an emerging technology that limits ischemia/reperfusion injury associated with preservation and may lead to improved outcomes following transplantation.

Patient‐reported outcomes in cirrhosis: A scoping review of the literature

Elliot B. Tapper, Fasiha Kanwal, Sumeet K. Asrani, Chanda Ho, Nadia Ovchinsky, John Poterucha, Avegail Flores, Judith E. Smith, Victor Ankoma‐Sey, Bruce Luxon, Michael L. Volk – 22 December 2017 – Patients with cirrhosis seek improvement in their symptoms, functioning, quality of life, and satisfaction with the care they receive. However, these patient‐reported outcomes (PROs) are not routinely measured for clinical care, research, or quality improvement.

Subscribe to